Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Pelabresib in Myelofibrosis: Exploring Disease Modification and Immune Response

Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis

Videos

Panelists discuss how myelofibrosis management involves a blend of medications, supportive care, and potential stem cell transplantation, with a focus on Janus kinase inhibitors and investigational agents like pelabresib for modifying disease progression, as well as the findings from the MANIFEST-2 trial regarding spleen volume reduction and biomarker data.

Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.

Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making

Panelists discuss how Janus kinase (JAK) inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, as well as investigational agents like pelabresib and navitoclax, target the dysregulated JAK-STAT pathway to manage symptoms and potentially modify disease progression in myelofibrosis.

Approved and Investigational Agents for Myelofibrosis

Panelists discuss approved and emerging therapies for myelofibrosis, focusing on how these treatments aim to modify the disease and improve patient outcomes.

Disease Modification Strategies and Unmet Needs in Myelofibrosis

Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.

MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction

Panelists discuss disease-modifying biomarker data from the MANIFEST-2 study investigating pelabresib in myelofibrosis.

Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib

Panelists discuss the safety profile of the pelabresib and ruxolitinib combination in myelofibrosis.

Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).

Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis

EP: 1.Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making

EP: 2.Approved and Investigational Agents for Myelofibrosis

EP: 3.Disease Modification Strategies and Unmet Needs in Myelofibrosis

EP: 4.MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction

EP: 5.Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib

EP: 6.Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis

EP: 7.Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders